Attached files
file | filename |
---|---|
EX-31.1 - EXHIBIT 31.1 - AYTU BIOPHARMA, INC | v465720_ex31-1.htm |
EX-31.2 - EXHIBIT 31.2 - AYTU BIOPHARMA, INC | v465720_ex31-2.htm |
EX-10.1 - EXHIBIT 10.1 - AYTU BIOPHARMA, INC | v465720_ex10-1.htm |
10-Q - 10-Q - AYTU BIOPHARMA, INC | v465720_10q.htm |
Exhibit 32.1
AYTU BIOSCIENCE, INC.
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the filing of the quarterly report on Form 10-Q for the quarter ended March 31, 2017 (the “Report”) by Aytu BioScience, Inc. (the “Company”), each of the undersigned hereby certifies that:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: May 11, 2017 | /s/ Joshua R. Disbrow |
Joshua R. Disbrow | |
Chief Executive Officer | |
Dated: May 11, 2017 | /s/ Gregory A. Gould |
Gregory A. Gould | |
Chief Financial Officer |